Pharmaceutical

STAT+: 12,000 diseases lack treatments. One doctor thin...

Using a unique AI tool, built from a half-dozen other algorithms, Every Cure is ...

STAT+: Vinod Khosla’s bold AI prediction, digital thera...

In the latest edition of STAT's Health Tech newsletter: Vinod Khosla's bold AI p...

Palobiofarma and FPWR partner to develop Prader Willi s...

The Phase II clinical trial will assess the efficacy and safety of PBF-999 in re...

Regeneron reports 7 per cent rise in Q1 2023 total revenue

Dupixent’s worldwide net sales increased by 37% to $2.49bn Q1 to Q1 2022-23.

UK negotiates reform for branded drug payment amidst in...

The UK government opens negotiations with industry and NHS representatives to cr...

How pharmaceutical firms are making their supply chains...

Pharmaceutical firms face a daunting but unavoidable challenge of creating digit...

TFF and NIEHS partner to develop powder formulations fo...

NIEHS and TFF will assess the TFF-HMW-HA formulations’ therapeutic efficacy and ...

Sanofi Canada’s Dupixent receives approval to treat EoE

Dupixent was initially approved to treat moderate-to-severe atopic dermatitis in...

CHMP recommends full marketing approval for Gilead Scie...

Hepcludex has also received breakthrough therapy and orphan drug designations fr...

Siegfried buys 95% stake in biotechnology firm DiNAMIQS

The deal includes an option for Siegfried to purchase the remaining 5% five year...

WHO declares end of Covid-19 public health emergency

The WHO ended the public health emergency for Covid-19 as the pharma industry co...

FDA raises alarm about weight-gain supplement apetamin

The US FDA has warned that the illegally imported supplement apetamin has been l...

STAT+: A new list ranks large pharmaceutical companies ...

Idea Pharma ranks the largest pharmaceutical companies based on two measures: wh...

12,000 diseases lack treatments. One doctor thinks gene...

Using a unique AI tool, built from a half-dozen other algorithms, Every Cure is ...

STAT+: Option Care takes over Amedisys in ‘perplexing’ ...

Option Care Health is buying Amedisys in an all-stock merger valued at $3.6 bill...

Vinod Khosla’s bold AI prediction, digital therapeutics...

In the latest edition of STAT's Health Tech newsletter: Vinod Khosla's bold AI p...